Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Angelini Pharma Expands Neuroscience Portfolio with $550M+ Deal for Preclinical Brain Health Asset

Angelini Pharma Expands Neuroscience Portfolio with $550M+ Deal for Preclinical Brain Health Asset

Italian pharmaceutical company Angelini Pharma has entered into a significant licensing agreement with South Korean biotech firm Sovargen, securing rights to a promising preclinical asset for brain health conditions. The deal, valued at over $550 million, marks Angelini's latest move in strengthening its neuroscience pipeline and underscores the company's commitment to addressing unmet needs in neurological and mental health disorders.

NoahAI News9/23/2025
Roche Unveils Ambitious Strategy to Become Top 3 Obesity Player by 2030

Roche Unveils Ambitious Strategy to Become Top 3 Obesity Player by 2030

Roche, the Swiss pharmaceutical giant, has announced its intent to become a leading force in the obesity treatment market, aiming to secure a position among the top three companies in the field before 2030. The strategy, unveiled by Roche Pharma CEO Teresa Graham at the company's Pharma Day in London, outlines a comprehensive approach to developing and commercializing obesity treatments.

NoahAI News9/22/2025
Roche's Giredestrant Shows Promise in Phase 3 Breast Cancer Trial

Roche's Giredestrant Shows Promise in Phase 3 Breast Cancer Trial

Roche has reported positive results from a phase 3 trial of its oral selective estrogen receptor degrader (SERD) giredestrant, marking a significant development in the treatment of breast cancer. The study, known as evERA, met its co-primary endpoints, potentially paving the way for regulatory filings and adding a new contender to the evolving landscape of oral SERDs.

NoahAI News9/22/2025
Genfit Halts Liver Failure Program After Phase 2 Trial Setback

Genfit Halts Liver Failure Program After Phase 2 Trial Setback

Genfit, a French pharmaceutical company, has announced the discontinuation of its VS-01 development program for acute-on-chronic liver failure (ACLF) following a serious adverse event in a phase 2 clinical trial. This decision marks a significant setback for the company's liver disease portfolio and has prompted a strategic realignment of its research priorities.

NoahAI News9/22/2025
FDA's Transparency Initiative Sheds Light on Cell and Gene Therapy Challenges

FDA's Transparency Initiative Sheds Light on Cell and Gene Therapy Challenges

The U.S. Food and Drug Administration (FDA) has taken a significant step towards increased transparency in its decision-making processes, particularly concerning cell and gene therapies (CGTs). This move, characterized as "radical transparency" by the agency, involves the publication of complete response letters (CRLs) and provides valuable insights into the regulatory hurdles faced by CGT developers.

NoahAI News9/22/2025
EmVenio Clinical Research Emerges as New Force in Patient-Centric Clinical Trials

EmVenio Clinical Research Emerges as New Force in Patient-Centric Clinical Trials

EmVenio Clinical Research, a newly rebranded entity combining PCM Trials, EmVenio Research, and Clinical Trial Service, has announced its official launch. This strategic alignment aims to revolutionize clinical trial accessibility and patient engagement across the pharmaceutical industry.

NoahAI News9/22/2025
AbbVie's $1.2B Acquisition Signals New Era for Psychedelic Therapeutics

AbbVie's $1.2B Acquisition Signals New Era for Psychedelic Therapeutics

AbbVie's recent $1.2 billion acquisition of Gilgamesh Pharmaceuticals' lead depression drug has injected new life into the psychedelic therapeutics sector, marking a significant shift in Big Pharma's approach to mental health treatments. This move comes as the industry rebounds from setbacks and pushes forward with multiple late-stage clinical trials.

NoahAI News9/22/2025
Sanofi's MS Drug Tolebrutinib Faces FDA Delay Amid Ongoing Development Challenges

Sanofi's MS Drug Tolebrutinib Faces FDA Delay Amid Ongoing Development Challenges

Sanofi's journey to bring its investigational multiple sclerosis (MS) drug tolebrutinib to market has encountered another obstacle, as the U.S. Food and Drug Administration (FDA) extends its review period by three months. This development marks the latest in a series of challenges for the French pharmaceutical giant's BTK inhibitor, which has shown promise in certain MS indications despite setbacks in clinical trials.

NoahAI News9/22/2025
FDA Approves First-Ever Treatment for Barth Syndrome, Marking Milestone in Ultra-Rare Disease Therapeutics

FDA Approves First-Ever Treatment for Barth Syndrome, Marking Milestone in Ultra-Rare Disease Therapeutics

In a groundbreaking development for the pharmaceutical industry and rare disease community, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Stealth BioTherapeutics' Forzinity (elamipretide) for the treatment of Barth syndrome. This decision marks a significant milestone as Forzinity becomes the first FDA-authorized therapy for this ultra-rare, life-limiting pediatric mitochondrial disease.

NoahAI News9/22/2025
VectorY and Shape Therapeutics Forge $1.2B+ Partnership for Brain-Penetrant Gene Therapies

VectorY and Shape Therapeutics Forge $1.2B+ Partnership for Brain-Penetrant Gene Therapies

VectorY Therapeutics and Shape Therapeutics have announced a groundbreaking collaboration potentially worth over $1.2 billion, focusing on the development of novel gene therapies for neurodegenerative diseases. The partnership, revealed on September 18, 2025, centers around Shape's innovative adeno-associated virus (AAV) capsid technology designed to penetrate deep into the brain.

NoahAI News9/19/2025
Pharmaceutical Industry Faces Major Layoffs Amid Restructuring and Cost-Cutting Measures

Pharmaceutical Industry Faces Major Layoffs Amid Restructuring and Cost-Cutting Measures

In a sweeping wave of restructuring and cost-cutting initiatives, six major pharmaceutical companies are set to eliminate over 39,000 jobs globally. This significant workforce reduction comes as the industry grapples with changing market dynamics, particularly in the obesity treatment sector, and a push for increased operational efficiency.

NoahAI News9/19/2025
Pharmaceutical Giants Announce Major Layoffs in New Jersey Amid Cost-Cutting Measures

Pharmaceutical Giants Announce Major Layoffs in New Jersey Amid Cost-Cutting Measures

Novo Nordisk and Bristol Myers Squibb (BMS) have unveiled significant workforce reductions in New Jersey, marking a substantial shift in the pharmaceutical landscape as both companies pursue aggressive cost-saving strategies.Novo Nordisk, the Danish pharmaceutical giant, has swiftly implemented its recently announced restructuring plan by laying off 263 employees at its U.S. headquarters in Plainsboro, New Jersey. This move comes as part of a broader initiative to reduce its global workforce by 9,000 employees, representing 11% of the company's total staff.

NoahAI News9/19/2025
«1...535455...67»